General
Preferred name
TADALAFIL
Synonyms
Cialis ()
IC-351 ()
IC351 ()
Tadalafil (IC351) ()
Tadalafil-d3 ()
Tadalafil component of opsynvi ()
Chewtadzy ()
Tadliq ()
Tadalafil mylan ()
NSC-750236 ()
Trans-tadalafil ()
Adcirca ()
LY-450190 ()
Tadalafil component of entadfi ()
Talmanco (previously tadalafil generics) ()
Tadalafilo ()
Adcirca (previously tadalafil lilly) ()
NSC-759172 ()
Tadalafil lilly ()
LY450190 ()
ADCIRCA ()
ADCIRCA (PREVIOUSLY TADALAFIL LILLY) ()
CHEWTADZY ()
TADALAFIL COMPONENT OF ENTADFI ()
TADALAFIL COMPONENT OF OPSYNVI ()
TADALAFIL LILLY ()
TADALAFIL MYLAN ()
TADALAFILO ()
TADLIQ ()
TALMANCO (PREVIOUSLY TADALAFIL GENERICS) ()
TRANS-TADALAFIL ()
Tadalafil (CRM) ()
P&D ID
PD000348
CAS
1242099-07-5
171596-29-5
960226-55-5
Tags
available
drug
Approved by
FDA
First approval
2002
2003
Drug indication
Erectile dysfunction
Benign prostatic hyperplasia
Drug Status
approved
investigational
Max Phase
4.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
MOA Penile erection during sexual stimulation is achieved by the relaxation of penile arteries and corpus cavernosal smooth muscles, leading to increased blood flow to the organ. This response is mediated by the release of nitric oxide (NO) from nerve terminals and endothelial cells, which stimulates the synthesis of cGMP in smooth muscle cells. Cyclic GMP causes smooth muscle relaxation and increased blood flow into the corpus cavernosum, and is degraded by the cGMP specific phosphodiesterase type 5 (PDE5) in the corpus cavernosum located around the penis. Tadalafil inhibits PDE5 and thereby enhances erectile function by increasing the amount of cGMP available.
DESCRIPTION Tadafil is a phosphodiesterase type 5 (PDE5) inhibitor. (GtoPdb)
PRICE 29
DESCRIPTION Tadalafil (IC-351) is a PDE5 inhibitor with an IC50 value of 1.8 nM.
DESCRIPTION Potent and selective PDE4B inhibitor (Tocris Bioactive Compound Library)
DESCRIPTION Tadalafil is a potent inhibitor of phosphodiesterase. Tadalafil is an orally administered drug used to treat male erectile dysfunction. (Enamine Bioactive Compounds)
DESCRIPTION Tadalafil (IC-351) is a carboline-based compound with vasodilatory activity that selectively inhibits the cyclic guanosine monophosphate (cGMP)-specific type 5 phosphodiesterase (PDE-5), preventing cGMP degradation in the smooth muscle of the corpus cavernosa and corpus spongiosum of the penis, thereby causing prolonged muscle relaxation, vasodilation, and enhanced penile erection. (TargetMol Bioactive Compound Library)
Cell lines
3
Organisms
4
Compound Sets
37
Cayman Chemical Bioactives
14024
41133
25030
ChEMBL Approved Drugs
CHEMBL779
ChEMBL Drugs
CHEMBL779
Concise Guide to Pharmacology 2017/18
7299
Concise Guide to Pharmacology 2019/20
7299
Concise Guide to Pharmacology 2021/22
7299
Concise Guide to Pharmacology 2023/24
7299
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DB00820
DrugBank Approved Drugs
DB00820
DrugCentral
2553
DrugCentral Approved Drugs
2553
DrugMAP
DMJZHT1
DrugMAP Approved Drugs
DMJZHT1
Enamine Bioactive Compounds
EBC-09118
Enamine BioReference Compounds
EU-OPENSCREEN Bioactive Compound Library
EOS100596
EUbOPEN Chemogenomics Library
EUB0002731
Guide to Pharmacology
7299
Ki Database
tadalafil
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL779
Mcule NIBR MoA Box Subset
MCULE-1208599456
MedChem Express Bioactive Compound Library
HY-90009A
Natural product-based probes and drugs
NCATS Inxight Approved Drugs
742SXX0ICT
NIH Clinical Collections (NCC)
Novartis Chemogenetic Library (NIBR MoA Box)
NPC Screening Collection
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
Tadalafil(Cialis)
TargetMol Bioactive Compound Library
T1398
The Spectrum Collection
Tocris Bioactive Compound Library
6311
VGSC-DB
NA0100
NA0101
ZINC Tool Compounds
ZINC000003993855
External IDs
57
Properties
(calculated by RDKit )
Molecular Weight
389.14
Hydrogen Bond Acceptors
4
Hydrogen Bond Donors
1
Rotatable Bonds
1
Ring Count
6
Aromatic Ring Count
3
cLogP
2.21
TPSA
74.87
Fraction CSP3
0.27
Chiral centers
2.0
Largest ring
6.0
QED
0.69
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
Apoptosis
PDE5
phosphodiesterase
PDE11A, PDE5A
Phosphodiesterase (PDE)
PDE
Primary Target
Phosphodiesterases
MOA
Inhibitor
Phosphodiesterase V (PDE5A) Inhibitors
phosphodiesterase inhibitor
Member status
member
Indication
erectile dysfunction
Therapeutic Indication
Male Sexual Dysfunction
Therapeutic Class
Cardiovascular
Antiimpotence Agents
Pathway
Metabolism
Metabolic Enzyme/Protease
VGSC Target
Nav1.5
Recommended Cell Concentration
1 uM
Source data